Elizabeth Griffiths, MD

Associate Professor
Director of MDS
Clinical Disease Team Leader
Department of Medicine
Roswell Park Comprehensive Cancer Center
Associate Professor
Department of Medicine
Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo
Is this your physician?
Areas of Expertise: 
Myelodysplastic syndrome (MDS)
Inherited and Acquired Bone Marrow Failure Syndromes (including Aplastic Anemia)
Acute myeloid leukemia (AML)
Myeloproliferative diseases (MPD)
Acute lymphoblastic leukemia (ALL)
Chronic myeloid leukemia (CML)
Hematologic Oncology
Special Interests: 
Early Phase Clinical Trials
Inherited Myeloid Cancer Predisposition Syndromes
Translational Medicine


I joined Roswell Park’s Leukemia Service in the Department of Medicine in March 2010. I treat patients with blood disorders, specifically acute myeloid and lymphoid leukemias, as well as bone marrow failure syndromes such as aplastic anemia and myelodysplastic syndrome (MDS). The MDS Foundation recognizes our MDS program as an MDS Center of Excellence. I am an Associate Professor at the State University of New York (SUNY) at Buffalo and a faculty member of the Roswell Park Comprehensive Cancer Center-SUNY Buffalo graduate training programs in the departments of Pharmacology and Therapeutics, Translational Medicine and Immunology.

I joined Roswell Park following completion of a five-year medical oncology and hematology fellowship at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in Baltimore, MD, where I also completed my internal medicine residency, in 2005. I completed my medical training at the University of North Carolina School of Medicine, Chapel Hill, NC, in 2002, earning my degree as a Doctor of Medicine with Distinction.

I am board certified in hematology, oncology and internal medicine and hold medical licenses in New York and Maryland. I am a member of multiple professional organizations, including the American Society of Hematology, the American Association for Cancer Research, the Society for Immunotherapy of Cancer and the American Society of Oncology.

My research is focused on the mechanism of hypomethylating drugs (HMAs) in patients with myeloid cancer, specifically the contribution of the immune system to these responses. We have examined how HMAs can cause re-expression of proteins in cancer cells that can be targeted by the immune system. I have authored/co-authored more than 50 peer-reviewed publications.


Education and Training: 
2002 - University of North Carolina School of Medicine, Chapel Hill, NC
2005 - Internal Medicine - Johns Hopkins Hospital, Baltimore, MD
2010 - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD
Board Certification: 
2008 - Hematology - American Board of Internal Medicine
2009 - Oncology - American Board of Internal Medicine
2005 - Internal Medicine - American Board of Internal Medicine

Is this your physician?